Spero (SPRO) Q4 2025 earnings review
A Transformational Quarter: From Heavy Burn to Milestone Profitability
Spero completed a massive financial pivot in Q4, shifting from heavy R&D burn to milestone-driven profitability. Revenue exploded to $41.3 million (up 175% YoY), while R&D expenses plummeted 81% to $5.6 million following the early, successful halt of the Phase 3 PIVOT-PO trial. This reversing dynamic generated a $31.5 million Net Income profit, radically altering Spero's trajectory. With the Tebipenem HBr NDA resubmitted to the FDA and a PDUFA date set for June 2026, the company has officially transitioned into a single-asset commercial waiting game, heavily reliant on partner GSK.
🐂 Bull Case
The Phase 3 PIVOT-PO trial was stopped early for efficacy, proving tebipenem HBr's non-inferiority to IV antibiotics for cUTI. The NDA is submitted, triggering a $25M milestone, and the path to FDA approval is clear.
With major clinical trials concluded, operating expenses have collapsed. Spero is fully funded into 2028, removing any near-term dilution risk ahead of commercial launch.
🐻 Bear Case
Following the discontinuation of SPR206 and the clinical failure of SPR720, Spero has no backup pipeline. If the FDA rejects tebipenem HBr in June 2026, the company's value drops to cash.
Future revenue is 100% dependent on GSK's ability to market and sell tebipenem HBr. Spero has surrendered control over launch trajectory and market penetration.
⚖️ Verdict: 🟢
Bullish. Spero executed its primary directive perfectly: it got tebipenem HBr through Phase 3, successfully handed it off to a deep-pocketed partner, and extended its cash runway to 2028. While single-asset risk remains, the near-term financial and clinical overhangs have been eliminated.
Key Themes
R&D Cost Collapse Powers Profitability
Reversing trend. R&D expenses decelerated massively throughout 2025, culminating in a drop from $28.8M in 24Q4 to just $5.6M in 25Q4. This 81% reduction is structural, driven by the early conclusion of the Phase 3 PIVOT-PO trial. This fundamentally shifts Spero from a cash-burning clinical biotech to a low-overhead holding company awaiting royalties.
GSK Partnership Engine Ignites
Accelerating. Collaboration revenue spiked to $39.7M in Q4 (related party + other), driving total revenue to $41.3M. Furthermore, the December 2025 NDA resubmission triggered a $25 million milestone payment received in Q1 2026. Spero remains eligible for up to $101 million tied to first commercial sales and tiered royalties up to low double-digits.
Disruptive Innovation in cUTI Standard of Care
Tebipenem HBr is positioned to be a first-in-class oral carbapenem. By allowing patients with complicated multi-drug resistant urinary tract infections to take an oral pill rather than requiring hospitalization for IV therapy, it offers a massive cost-saving proposition for the healthcare system. The PIVOT-PO trial proved it is non-inferior to IV imipenem-cilastatin, validating the science.
Pipeline Wipeout Leaves Dangerous Single-Asset Exposure
While management is celebrating Q4's profitability, the reality is Spero's backup engine is dead. The SPR720 program for NTM-PD failed its Phase 2a trial with severe dose-limiting safety signals (including 3 cases of grade 3 hepatotoxicity), and SPR206 was discontinued. This contradicts the narrative of a robust biotech platform; Spero is now entirely a tebipenem HBr tracking stock.
Total Reliance on Partner Commercial Execution
Spero has licensed away all commercial rights (excluding certain Asian territories). If GSK deprioritizes the launch, encounters manufacturing hiccups, or struggles with pricing negotiations, Spero has no levers to pull. The company is completely captive to GSK's internal resource allocation.
Long Gap Before Commercial Royalties
Despite Q4 net income, investors face a massive waiting period. The PDUFA date is June 18, 2026. This means commercial launch and subsequent sales-based milestones and royalties will likely not materialize until late 2026 or early 2027, creating a potential dead zone for stock catalysts.
Other KPIs
Decelerating aggressively. Down 60% from $96.8 million in FY24. This confirms the permanent step-down in clinical trial costs following the PIVOT-PO completion, establishing a much lower baseline for ongoing cash burn.
Reversing. Achieved full-year profitability, a massive turnaround from a net loss of $68.6 million in FY24. This was primarily driven by the timing of massive collaboration revenue milestones hitting in the fourth quarter.
Stable. The year-end balance of $40.3M does not include the critical $25M milestone payment from GSK, which arrived in Q1 2026. Factoring in that payment, Spero's liquidity position is remarkably strong for its current low-burn state.
Guidance
Stable. Management extended its cash runway forecast into 2028 (up from previous estimates of Q2 2026 in prior quarters). This acceleration in runway duration is due to the $25M GSK milestone and the severe reduction in operating expenses. The company is fully funded well past the June 2026 PDUFA date.
This is the single most important date for the company. FDA approval will trigger the next phase of the GSK partnership, including up to $101 million tied to first commercial sales.
Key Questions
Capital Allocation Void
With the pipeline effectively cleared of SPR720 and SPR206, and cash runway extended into 2028, what is the strategic plan for capital? Will you acquire new early-stage assets, or return capital to shareholders if tebipenem HBr is approved?
FDA Manufacturing Inspections
Given the June 18, 2026 PDUFA date, are there any outstanding manufacturing facility inspections required by the FDA for tebipenem HBr, and has GSK secured all necessary supply chain validations?
Commercial Launch Prep
How closely is Spero involved in GSK's pre-commercialization strategy, and what specific steps is the partner taking over the next 15 months to prepare the cUTI market for an oral carbapenem?